Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan.[2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives.[3] It is reported to have respiratory stimulant activity.[4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor.[5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.[6]
Clinical data | |
---|---|
Trade names | Broncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama[1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.038.135 |
Chemical and physical data | |
Formula | C21H24ClN3O3 |
Molar mass | 401.89 g·mol−1 |
3D model (JSmol) |
|
| |
|
Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.[7]